Lumacaftor/ivacaftor initiation in two liver transplantation patients under tacrolimus and antifungal azoles

We report the initiation of CFTR modulator lumacaftor/ivacaftor combination (LUM/IVA) in two adolescents with cystic fibrosis who were treated with antifungal azoles (AZO) and tacrolimus (TCS) for liver transplantation. Despite multiple drug‐drug interactions, maintaining therapeutic TCS levels was achievable. During the following year, LUM/IVA was well tolerated, providing clinical benefits.

[1]  P. Barry,et al.  CFTR modulator therapy in patients with cystic fibrosis and an organ transplant. , 2018, Paediatric respiratory reviews.

[2]  G. Verleden,et al.  Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  T. Noah,et al.  Therapeutic challenges posed by critical drug–drug interactions in cystic fibrosis , 2016, Pediatric pulmonology.